Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ: SAGE )

7.000 +0.060 (+0.86%)
Streaming Delayed Price Updated: 1:45 PM EST, Jan 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
June’s Best and Worst Performing Russell 1,000 Stocks
The month of June, the second quarter and the first half of 2021 are almost in the bag. 
Via Talk Markets
How Bad Is Biogen's Latest Bad News?
The drugmaker has had one big clinical setback and another less serious disappointment in recent weeks. 
Via The Motley Fool
What Happened to Sage Therapeutics Stock?
Sage has been struggling for some time to bring its flagship antidepressant to the market. 
Via The Motley Fool
Looking For Bargains Among The Rubble
Last week was tough. Nearly everything publicly traded took a hit. In this article I drill down into the market to take account of where the damage was the worst, and maybe identify a few bargains... 
Via Talk Markets
Here's Why Sage Therapeutics Tanked This Week
The neuroscience-focused biotech company didn't give investors the result they wanted. 
Via The Motley Fool
Biogen Discontinues Tau Antibody Program For Alzheimer's After Mid-Stage Study Flops
Biogen Inc (NASDAQ: BIIB) has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, of which one has just been canned. The... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2021
Upgrades According to Piper Sandler, the prior rating for First Bancorp (NASDAQ: 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Morgan Stanley raised NIKE, Inc. (NYSE:NKE) price ta... 
Via Benzinga
44 Biggest Movers From Yesterday
Gainers Alzamend Neuro, Inc. (NASDAQ: ALZN) shares jumped 170% to close at $13.50 on Tuesday after the company priced its IPO at $5 per share. Alfi, Inc. (NASDAQ: ALF) shares... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Mid-Afternoon Market Update: Nasdaq Down 100 Points; Clearside Biomedical Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 0.19% to 34,326.95 while the NASDAQ fell 0.70% to 14,074. The S&P also fell, dropping 0.12% to 4,249.99. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Clearside Biomedical (NASDAQ:CLSD) stock moved upwards by 26.21% to $3.81 during Tuesday's regular session. As of 12:30 EST, this security is trading at a... 
Via Benzinga
Here's Why Sage Therapeutics Stock Is Sliding Today
Long-awaited clinical trial results weren't as successful as hoped. 
Via The Motley Fool
Mid-Day Market Update: Crude Oil Rises 1%; Sage Therapeutics Shares Slide
Midway through trading Tuesday, the Dow traded down 0.45% to 34,238.18 while the NASDAQ fell 0.53% to 14,099.27. The S&P also fell, dropping 0.25% to 4,244.45. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
34 Stocks Moving In Tuesday's Mid-Day Session
Gainers HMG/Courtland Properties, Inc. (NYSE: HMG) shares surged 133% to $27.80. Alfi, Inc. (NASDAQ: ALF) shares jumped 82.1% to $6.21 after the company inked an agreement with... 
Via Benzinga
Biogen Analyst Raises Price Target On Higher Chance Of Success For Depression Drug
Biogen Inc. (NASDAQ: BIIB) stock is seeing muted sentiment Tuesday as it emerges from the euphoria over Aduhelm approval, with the most recent trigger being lukewarm data for a... 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; US Retail Sales Drop 1.3% In May
Following the market opening Tuesday, the Dow traded down 0.34% to 34,275.92 while the NASDAQ fell 0.09% to 14,161.73. The S&P also fell, dropping 0.10% to 4,250.89. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Sage Stock Tumbles As Analysts Question Its 'Positive' Test In Depression
The results showed an improvement over placebo. But that improvement waned over time. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Clearside Biomedical (NASDAQ:CLSD) stock increased by 50.99% to $4.56 during Tuesday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
Why Sage Therapeutics (SAGE) Stock Is Falling Despite Meeting Primary Endpoint In Major Depressive Disorder Trial With Zuranolone
Looking to make a comeback after a big Phase 3 flop, Sage Therapeutics Inc (NASDAQ: SAGE) revealed data from another Phase 3 evaluating zuranolone in patients with... 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Sage Therapeutics - Biogen's Zuranolone Tops Placebo In Reducing Depressive Symptoms
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced data from WATERFALL Phase 3 study evaluating zuranolone (SAGE-217/... 
Via Benzinga
With Aduhelm Approval Behind Biogen, 5 Catalysts For Investors To Watch
Biogen Inc. (NASDAQ: BIIB) made history of sorts with the FDA approval for its Alzheimer's treatment Aduhelm. Notwithstanding the still-raging debate over the decision, an... 
Via Benzinga
Exposures Product Safety
3 Biotech Stocks With Huge Catalysts in June
Binary events expected this month could have enormous implications for these drugmakers and their shareholders. 
Via The Motley Fool
Exposures Product Safety
The Fight Against Alzheimer's Reaches A Moment Of Truth For Biogen, Other Biotech Stocks
The FDA will soon review aducanumab, possibly the first new Alzheimer's treatment in years. Stakes are high for Biogen stock — and other biotech stocks too. 
Via Investor's Business Daily
Exposures Product Safety
Sage Therapeutics Inc (SAGE) Q1 2021 Earnings Call Transcript
SAGE earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Sage-Biogen Essential Tremor Candidate Hits Primary Endpoint Goal, But 38% Of People Drop Out
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have scored their first but narrow win after signing their $3.1 billion deal last... 
Via Benzinga
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Earnings Scheduled For May 4, 2021
Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million. •... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.